Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna（MRNA）股价周五盘前下跌 2.5%，原因是市场担忧美国疾病控制与预防中心（CDC）新成立的顾问小组是否会支持该公司呼吸道合胞病毒（RSV）疫苗在更广泛年龄组中的使用。 Moderna 的 RSV 疫苗 mRESVIA 于周四获得美国批准，可扩大用于 18 至 59 岁的高危成年人，但在该年龄组使用前，需获得美国疾控中心的推荐。该疫苗此前已获批用于 60 岁及以上成年人。

Moderna's massive covid vaccine sales and prepayments left it with $18.2 billion in cash at the end of 2022, but that balance is steadily shrinking due to previous share repurchases (more than $5 ...